Anti-addictive actions of an iboga alkaloid congener: a novel mechanism for a novel treatment

  title={Anti-addictive actions of an iboga alkaloid congener: a novel mechanism for a novel treatment},
  author={Isabelle M. Maisonneuve and Stanley D. Glick},
  journal={Pharmacology Biochemistry and Behavior},
18-Methoxycoronaridine: a potential new treatment for obesity in rats?
Data suggest that antagonism of α3β4 nicotinic receptors may be involved in the regulation of intake of palatable substances regardless of its caloric value and may participate in maintaining obesity.
Effect of Iboga Alkaloids on µ-Opioid Receptor-Coupled G Protein Activation
Evidence regarding the activation of μ-opioid receptor (MOR)-related G proteins by iboga alkaloids is replicated and extended to suggest a novel mechanism of action, and further justify the search for alternative targets of ibogamine skeleton compounds.
Brain regions mediating α3β4 nicotinic antagonist effects of 18- MC on methamphetamine and sucrose self-administration
Results are consistent with the hypothesis that 18-MC decreases methamphetamine self-administration by indirectly modulating the dopaminergic mesolimbic pathway via blockade of α3β4 nicotinic receptors in the habenulo-interpeduncular pathway and the basolateral amygdala.
18-Methoxycoronaridine, a potential anti-obesity agent, does not produce a conditioned taste aversion in rats
Behavioural Pharmacology of Novel Kappa Opioid Compounds
This study provides evidence to suggest the involvement of the serotonin system in Sal A and DS1 induced depression and a difference in modulation of serotonin transporter function by novel and traditional KOPr agonists was observed.
Novel pharmacotherapeutic treatments for cocaine addiction
The most recent human clinical trials of potential medications for treatment of cocaine dependence are discussed as well as pre-clinical studies for another promising agent, levo tetrahydropalmatine, whose mechanism remains to be determined.


Development of Novel Medications for Drug Addiction: The Legacy of an African Shrub
All of the data indicate that 18‐MC should be safer than ibogaine and at least as efficacious as an anti‐addictive medication.
Interactions between ibogaine, a potential anti-addictive agent, and morphine: an in vivo microdialysis study.
18‐MC reduces methamphetamine and nicotine self‐administration in rats
It is suggested that a nicotinic antagonist action of 18-MC contributes to its putative anti-addictive efficacy and is least effective in decreasing methamphetamine self-administration and most potent in decreasing nicotine self-Administration.
Attenuation of Alcohol Consumption by a Novel Nontoxic Ibogaine Analogue (18-Methoxycoronaridine) in Alcohol-Preferring Rats